Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 35
- +6 vs. Q2 2022
- Portfolio value
- $244.9M
- +$99.5M (+68.4%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SYRESpyre Therapeutics, Inc. | COM | 1,000,000 | $526.0K | 0.2% | +75,000+8.1% | Added | History |
| BIIBBiogen Inc. | COM | 3,750 | $1.00M | 0.4% | +3,750 | New | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 65,000 | $1.59M | 0.7% | +65,000 | New | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 25,000 | $1.63M | 0.7% | +25,000 | New | History |
| DSGNDesign Therapeutics, Inc. | COM | 100,000 | $1.67M | 0.7% | −175,000−63.6% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 120,000 | $2.05M | 0.8% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 200,000 | $2.10M | 0.9% | +200,000 | New | History |
| RAPTRAPT Therapeutics, Inc. | COM | 90,000 | $2.17M | 0.9% | −75,000−45.5% | Reduced | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 300,000 | $2.33M | 1.0% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 150,000 | $2.49M | 1.0% | +150,000 | New | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 60,000 | $2.79M | 1.1% | +60,000 | New | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 200,000 | $2.83M | 1.2% | +50,000+33.3% | Added | History |
| BPMCBlueprint Medicines Corp | COM | 65,000 | $4.28M | 1.7% | +65,000 | New | History |
| KZRKezar Life Sciences, Inc. | COM | 525,000 | $4.52M | 1.8% | +75,000+16.7% | Added | History |
| ATXSAstria Therapeutics, Inc. | COM | 500,000 | $4.52M | 1.8% | +500,000 | New | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 75,000 | $4.64M | 1.9% | −25,000−25.0% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 200,000 | $4.81M | 2.0% | −25,000−11.1% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 500,000 | $5.22M | 2.1% | −500,000−50.0% | Reduced | History |
| ALTAltimmune, Inc. | COM NEW | 435,000 | $5.55M | 2.3% | +435,000 | New | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 525,000 | $6.62M | 2.7% | +200,000+61.5% | Added | History |
| KRTXKaruna Therapeutics, Inc. | COM | 30,000 | $6.75M | 2.8% | −15,000−33.3% | Reduced | History |
| ISEEIVERIC bio, Inc. | COM | 463,700 | $8.32M | 3.4% | −36,300−7.3% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 360,000 | $8.64M | 3.5% | +35,000+10.8% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 600,000 | $8.95M | 3.7% | −300,000−33.3% | Reduced | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 95,000 | $9.81M | 4.0% | +20,000+26.7% | Added | History |
| RVNCRevance Therapeutics, Inc. | COM | 390,000 | $10.5M | 4.3% | +390,000 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 535,000 | $11.0M | 4.5% | −65,000−10.8% | Reduced | History |
| CTICCti Biopharma Corp | COM | 2,000,000 | $11.6M | 4.8% | +1,200,000+150.0% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 110,000 | $12.2M | 5.0% | −20,000−15.4% | Reduced | History |
| MRTXMirati Therapeutics, Inc. | COM | 175,000 | $12.2M | 5.0% | +65,000+59.1% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 300,000 | $13.4M | 5.5% | +75,000+33.3% | Added | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 550,000 | $15.5M | 6.3% | +550,000 | New | History |
| RLMDRelmada Therapeutics, Inc. | COM | 425,000 | $15.7M | 6.4% | +175,000+70.0% | Added | History |
| RETAReata Pharmaceuticals Inc | CL A | 725,000 | $18.2M | 7.4% | +725,000 | New | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 275,000 | $18.8M | 7.7% | +50,000+22.2% | Added | History |
Options (9)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | $39.7M | – |
| RLMDRelmada Therapeutics, Inc. | COM | $18.5M | – |
| DICEDICE Therapeutics, Inc. | COM | – | $14.2M |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | $14.1M | – |
| SGENSeagen Inc. | COM | – | $6.84M |
| AXSMAxsome Therapeutics, Inc. | COM | – | $6.69M |
| TCDATricida, Inc. | COM | – | $5.24M |
| RETAReata Pharmaceuticals Inc | CL A | – | $5.03M |
| ISEEIVERIC bio, Inc. | COM | – | $1.10M |
Sold out since Q2 2022 (6)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| SGENSeagen Inc. | COM | 35,000 | $6.19M | 4.3% | History |
| MRUSMerus N.V. | COM | 250,000 | $5.66M | 3.9% | History |
| ARVNArvinas, Inc. | COM | 110,000 | $4.63M | 3.2% | History |
| NMTR9 Meters Biopharma, Inc. | COM | 1,800,000 | $469.0K | 0.3% | History |
| DICEDICE Therapeutics, Inc. | COM | 30,000 | $466.0K | 0.3% | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 1,900 | $277.0K | 0.2% | History |